Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

ClinicalTrials.gov ID: NCT00800683

Public ClinicalTrials.gov record NCT00800683. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Safety in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 vs. Placebo, DB, Parallel Group, Randomized, Insulin Background Inclusive

Study identification

NCT ID
NCT00800683
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
133 participants

Conditions and interventions

Interventions

  • BI 1356 Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2008
Primary completion
Dec 31, 2010
Completion
Not listed
Last update posted
May 19, 2014

Started 2008

United States locations

U.S. sites
24
U.S. states
15
U.S. cities
23
Facility City State ZIP Site status
1218.43.10027 Boehringer Ingelheim Investigational Site Phoenix Arizona
1218.43.10011 Boehringer Ingelheim Investigational Site Chula Vista California
1218.43.10006 Boehringer Ingelheim Investigational Site Riverside California
1218.43.10021 Boehringer Ingelheim Investigational Site Whittier California
1218.43.10013 Boehringer Ingelheim Investigational Site Pembroke Pines Florida
1218.43.10009 Boehringer Ingelheim Investigational Site West Palm Beach Florida
1218.43.10018 Boehringer Ingelheim Investigational Site Decatur Georgia
1218.43.10022 Boehringer Ingelheim Investigational Site Chicago Illinois
1218.43.10015 Boehringer Ingelheim Investigational Site Shreveport Louisiana
1218.43.10016 Boehringer Ingelheim Investigational Site Kansas City Missouri
1218.43.10003 Boehringer Ingelheim Investigational Site Great Neck New York
1218.43.10004 Boehringer Ingelheim Investigational Site The Bronx New York
1218.43.10020 Boehringer Ingelheim Investigational Site Winston-Salem North Carolina
1218.43.10019 Boehringer Ingelheim Investigational Site Delaware Ohio
1218.43.10008 Boehringer Ingelheim Investigational Site Mentor Ohio
1218.43.10005 Boehringer Ingelheim Investigational Site Bethlehem Pennsylvania
1218.43.10007 Boehringer Ingelheim Investigational Site Carlisle Pennsylvania
1218.43.10001 Boehringer Ingelheim Investigational Site Providence Rhode Island
1218.43.10025 Boehringer Ingelheim Investigational Site Aiken South Carolina
1218.43.10023 Boehringer Ingelheim Investigational Site Austin Texas
1218.43.10024 Boehringer Ingelheim Investigational Site Austin Texas
1218.43.10014 Boehringer Ingelheim Investigational Site Dallas Texas
1218.43.10017 Boehringer Ingelheim Investigational Site Lufkin Texas
1218.43.10010 Boehringer Ingelheim Investigational Site Tacoma Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00800683, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 19, 2014 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00800683 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →